SPOTLIGHT -
Survival benefit for chemotherapy addition demonstrated for premenopausal patients with HR+/HER2– breast cancer
Investigators of the SWOG S1007 RxPONDER trial found a statistically significant improvement in invasive disease-free survival and distant relapse-free survival in premenopausal women who received adjuvant chemotherapy.
Read More